466 / 1726
International Evaluation of Radiotherapy Technology
Effectiveness in Cervical Cancer (INTERTECC): Phase II/III Trial
of Intensity Modulated Radiotherapy
New OAR of interest
• International multicenter Phase II/III Trial of IMRT (45-50.4 Gy) with Cisplatin CT
• Stage I-IVA cervix cancer, primary treatment or post-op, inclusion 425 patients
intended
• Primary Endpoint: Acute G3 Hematologic + G2 GI Toxicity
• Intended: Phase III randomized trial of
BM sparing IMRT
vs. IMRT/ 3D CRT
• Central IMRT QA (MDA and Wash U.)